Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: administration of intravenous lipid emulsion Clear all
Completed Phase 3 Interventional

Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children

NCT01194063
View directory record Official record
Conditions
Cholestasis
Interventions
Omega-3 fish oil lipid emulsion
Drug
Lead sponsor
Kapiolani Medical Center For Women & Children
Other
Eligibility
Up to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 9, 2026, 4:27 PM EDT
Terminated Phase 2 Interventional Results available

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

NCT02609984
View directory record Official record
Conditions
Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma, Metastatic Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Locally Advanced Sarcoma, Liposarcoma
Interventions
CMB305, atezolizumab
Biological
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
18
States / cities
Palo Alto, California • Santa Monica, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 9, 2026, 4:27 PM EDT
Recruiting Phase 4 Interventional

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

NCT06049680
View directory record Official record
Conditions
Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
Interventions
SMOFlipid® (lipid injectable emulsion)
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
1 Month to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Compassionate Use of Omegaven in Children

NCT02370251
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis, Cholestasis, Short Bowel Syndrome, Gastroschisis, Intestinal Atresia, Infant, Premature, Diseases, Cholestasis of Parenteral Nutrition
Interventions
Omegaven
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 9, 2026, 4:27 PM EDT
Terminated Phase 2 Interventional Results available

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury

NCT01325584
View directory record Official record
Conditions
Cancer, Hepatic Injury
Interventions
Omegaven
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 9, 2026, 4:27 PM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury

NCT01412359
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven®
Drug
Lead sponsor
Jeffrey Rudolph
Other
Eligibility
2 Months to 10 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 9, 2026, 4:27 PM EDT
Approved For Marketing No phase listed Expanded access

Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury

NCT02780193
View directory record Official record
Conditions
Cholestasis, Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
Up to 18 Years
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 9, 2026, 4:27 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
View directory record Official record
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Phase 3 Interventional

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

NCT00093249
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 9, 2026, 4:27 PM EDT
Withdrawn Phase 4 Interventional

Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age

NCT03481894
View directory record Official record
Conditions
Malnutrition
Interventions
Kabiven®, Compounded standard parenteral nutrition
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

NCT00666328
View directory record Official record
Conditions
Hypertension, Hemorrhage
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Increased Free Fatty Acids on Leptin Function

NCT01520454
View directory record Official record
Conditions
Obesity, Leptin Resistance
Interventions
Saline, Intralipid, Water, oral fat, Heparin
Drug · Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants

NCT00738101
View directory record Official record
Conditions
Cholestasis, Cholestasis of Parenteral Nutrition
Interventions
Omegaven
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Days to 5 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 9, 2026, 4:27 PM EDT
Not yet recruiting Phase 2 Interventional

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

NCT06052956
View directory record Official record
Conditions
Abscess
Interventions
Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose), Standard of care abscess drainage
Drug · Device · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates

NCT03387579
View directory record Official record
Conditions
Cholestasis of Parenteral Nutrition
Interventions
Smoflipid 20% Lipid Emulsion for Injection, Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Not applicable Interventional

Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury

NCT01089426
View directory record Official record
Conditions
Liver Injury
Interventions
Omegaven™, Historical Controls
Drug · Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 21 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury

NCT01845116
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven®
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
4 Weeks to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 9, 2026, 4:27 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

NCT02579265
View directory record Official record
Conditions
Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Interventions
Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
0 Weeks and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 9, 2026, 4:27 PM EDT
Completed No phase listed Observational

Prospective Cohort Study of Intravenous Lipid Emulsion for Resuscitating Critically-ill Poisoned Patients

NCT03107689
View directory record Official record
Conditions
Overdose
Interventions
administration of intravenous lipid emulsion
Other
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 9, 2026, 4:27 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration

NCT04584983
View directory record Official record
Conditions
Bilirubin Encephalopathy
Interventions
usual prescribed intralipid (UL) regimen, restricted prescribed intralipid (RL) regimen
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 27 Weeks
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 9, 2026, 4:27 PM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children

NCT02328768
View directory record Official record
Conditions
Total Parenteral Nutrition-Induced Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 9, 2026, 4:27 PM EDT
Not yet recruiting Phase 2 Interventional

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

NCT07179003
View directory record Official record
Conditions
Breast Abscess
Interventions
Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy
Procedure · Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis

NCT01173159
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 9, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

NCT01143064
View directory record Official record
Conditions
Brain Injuries
Interventions
Progesterone, Lipid emulsion without progesterone
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
16 Years to 70 Years
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 9, 2026, 4:27 PM EDT